-
Mashup Score: 0
The findings show that treatment with the COVID-19 oral antiviral can develop into different strains and spread.
Source: www.contagionlive.comCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 2COVID-19 Guideline, Part 1: Treatment and Management - 1 year(s) ago
IDSA has developed living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19 infection. Summarized here are the recommendations with comments related to the clinical practice guideline for the treatment and management of COVID-19.
Source: www.idsociety.orgCategories: Infectious Disease, Latest HeadlinesTweet-
ICYMI: IDSA has released updated evidence summaries and clarified remarks on the use of #molnupiravir in the treatment of patients with COVID-19: https://t.co/Z8teKU2IMj #COVID19Guidelines https://t.co/VjfAYqEmGp
-
-
Mashup Score: 7COVID-19 Guideline, Part 1: Treatment and Management - 1 year(s) ago
IDSA has developed living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19 infection. Summarized here are the recommendations with comments related to the clinical practice guideline for the treatment and management of COVID-19.
Source: www.idsociety.orgCategories: Infectious Disease, Latest HeadlinesTweet-
#COVID19Guidelines update! IDSA has released updated evidence summaries and clarified remarks on the use of #molnupiravir in the treatment of patients with COVID-19: https://t.co/InyRvQiYjp https://t.co/GStULaoq74
-
-
Mashup Score: 3
Specifically for older individuals and immunocompromised individuals, a year could be too long.
Source: Infection Control TodayCategories: Infectious Disease, Latest HeadlinesTweet-
Specifically for older individuals and immunocompromised individuals, a year could be too long. https://t.co/HBfjh9Rhbr #COVID-19 #booster #novavax #APhA @CDCgov #ACIP #bivalent #monovalent #vaccine #molnupiravir #Paxlovid
-
-
Mashup Score: 1NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals - 1 year(s) ago
NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
Source: www.jwatch.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Among patients vaccinated against #COVID19, molnupiravir did not reduce hospitalization or death but appeared to hasten self-reported recovery. https://t.co/H0PHwvUerY @RMKGandhi #molnupiravir https://t.co/jhmz18Z6lK
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Emergency Medicine, Latest HeadlinesTweet-
Our best-read article last March: #Ritonavir/nirmatrelvir & #molnupiravir were approved by the @US_FDA to treat #COVID19, and @poisonreview explained how to use these oral drugs. #FOAMtox #FOAMed https://t.co/XRJ1dU8njJ #Bestof2022 https://t.co/aJadiq6KIk
-
-
Mashup Score: 0Molnupiravir Doesn’t Decrease COVID-19 Deaths or Hospitalizations, but May Speed Recovery - 1 year(s) ago
Despite failing to meet primary trial endpoints, molnupiravir reduced the length of COVID-19 infection by 4.2 days in vaccinated patients.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
Despite failing to meet primary trial endpoints, #molnupiravir reduced the length of COVID-19 infection by 4.2 days in vaccinated patients. https://t.co/DuR8UtRWzh https://t.co/dCLRAe1AF3
-
-
Mashup Score: 98
Abstract
Background The safety, effectiveness and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, in patients in the co
Source: papers.ssrn.comCategories: Critical Care, Latest HeadlinesTweet-
A preliminary analysis from the PANORAMIC trial #molnupiravir arm has been made available at https://t.co/BGqr8JBRpS The authors conclude: https://t.co/x8N1fdGLCt
-
-
Mashup Score: 29
During a wave of SARS-CoV-2 omicron BA.2, initiation of novel oral antiviral treatments in hospitalised patients not requiring oxygen therapy on admission showed substantial clinical benefit. Our findings support the early use of oral antivirals in this population of patients.
Source: The Lancet Infectious DiseasesCategories: Expert Picks, Latest HeadlinesTweet-
This paper from Hong Kong looked at #molnupiravir and #Paxlovid in early HOSPITALIZED patients for #covid. Retrospective study from Feb 26-April 26, 2022 where patients who did not need oxygen on admission where started on either oral antiviral https://t.co/CwyVB0UE7q
-
-
Mashup Score: 10
Antivirals were associated with lower all-cause mortality and illness severity during BA.2
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
During the #Omicron BA.2 wave, antivirals #molnupiravir and #nirmatrelvir-ritonavir (#Paxlovid) appeared to have clinical benefit in hospitalized patients w/ mild-to-moderate #COVID-19 who did not require oxygen therapy: https://t.co/OQPTDcuzMQ @ingridhein #IDTwitter
-
New study raises concerns about the oral antiviral #molnupiravir and its impact on #COVID19 mutations. Researchers find that the antiviral may induce mutations in the virus genome. https://t.co/xMOdlNITQ1